A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2018
At a glance
- Drugs MSC 1 (Primary)
- Indications Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Northern Biologics
- 06 Apr 2018 Status changed from planning to not yet recruiting.
- 19 Jan 2017 New trial record
- 19 Dec 2016 According to a Northern Biologics media release, this study is expected to initiate in 2017.